CL2011003075A1 - Proteina precursora que comprende una secuencia repetitiva con propiedades de autoensamblaje que puede ser escindida en sus componentes, los que comprenden un peptido de interes y un peptido auxiliar de autoensamblaje; acido nucleico que la codifica; casete de expresion, vector; metodo de produccion; y su uso. - Google Patents

Proteina precursora que comprende una secuencia repetitiva con propiedades de autoensamblaje que puede ser escindida en sus componentes, los que comprenden un peptido de interes y un peptido auxiliar de autoensamblaje; acido nucleico que la codifica; casete de expresion, vector; metodo de produccion; y su uso.

Info

Publication number
CL2011003075A1
CL2011003075A1 CL2011003075A CL2011003075A CL2011003075A1 CL 2011003075 A1 CL2011003075 A1 CL 2011003075A1 CL 2011003075 A CL2011003075 A CL 2011003075A CL 2011003075 A CL2011003075 A CL 2011003075A CL 2011003075 A1 CL2011003075 A1 CL 2011003075A1
Authority
CL
Chile
Prior art keywords
self
peptide
assembling
vector
interest
Prior art date
Application number
CL2011003075A
Other languages
English (en)
Inventor
Daniel Hummerich
Burghard Fehr Marcus Schwalb Carsten Bruser Heike Liebmann
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of CL2011003075A1 publication Critical patent/CL2011003075A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Proteína precursora que comprende una secuencia repetitiva con propiedades de autoensamblaje, que puede ser escondida en sus componentes, los que comprenden un péptido de interés y un péptido auxiliar de autoensamblaje; ácido nucleico que la codifica; casete de expresión, vector; método de producción; y su uso.
CL2011003075A 2009-06-03 2011-12-02 Proteina precursora que comprende una secuencia repetitiva con propiedades de autoensamblaje que puede ser escindida en sus componentes, los que comprenden un peptido de interes y un peptido auxiliar de autoensamblaje; acido nucleico que la codifica; casete de expresion, vector; metodo de produccion; y su uso. CL2011003075A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09161837 2009-06-03

Publications (1)

Publication Number Publication Date
CL2011003075A1 true CL2011003075A1 (es) 2012-06-29

Family

ID=43298234

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011003075A CL2011003075A1 (es) 2009-06-03 2011-12-02 Proteina precursora que comprende una secuencia repetitiva con propiedades de autoensamblaje que puede ser escindida en sus componentes, los que comprenden un peptido de interes y un peptido auxiliar de autoensamblaje; acido nucleico que la codifica; casete de expresion, vector; metodo de produccion; y su uso.

Country Status (20)

Country Link
US (1) US9481719B2 (es)
EP (1) EP2437769B1 (es)
JP (1) JP5730293B2 (es)
KR (2) KR101834018B1 (es)
CN (1) CN102724992B (es)
AR (1) AR076977A1 (es)
AU (1) AU2010255732B8 (es)
BR (1) BRPI1011144B8 (es)
CA (1) CA2763626A1 (es)
CL (1) CL2011003075A1 (es)
CR (1) CR20110619A (es)
EC (1) ECSP12011577A (es)
ES (1) ES2763168T3 (es)
IL (1) IL216619A0 (es)
MX (1) MX2011012906A (es)
NZ (2) NZ615847A (es)
PE (1) PE20121033A1 (es)
RU (1) RU2548815C2 (es)
TW (1) TWI429750B (es)
WO (1) WO2010139736A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2597743A1 (en) * 2005-02-24 2006-08-31 The University Of Queensland Peptide networks
WO2012079125A1 (en) * 2010-12-14 2012-06-21 The University Of Queensland Designed biosurfactants, their manufacture, purification and use
CN103740661B (zh) * 2012-05-10 2015-06-03 江南大学 一种提高酶热稳定性的方法
CN103756979B (zh) * 2012-05-10 2015-07-08 江南大学 一种提高酶热稳定性的方法
CN103740659B (zh) * 2012-05-10 2015-06-03 江南大学 一种提高酶热稳定性的方法
CA2877301A1 (en) * 2012-06-20 2013-12-27 Michael J. Heller Dynamic biomimetic synzyme catalyst, catalysis, and catalytic systems
CN104755502B (zh) * 2012-10-12 2018-05-18 清华大学 多肽的产生和纯化方法
WO2017055587A1 (de) * 2015-10-01 2017-04-06 Basf Se Rekombinante herstellung von peptiden
KR101976923B1 (ko) * 2017-05-10 2019-05-10 건국대학교 산학협력단 D-루이신 치환을 통해 항균 효과를 증진시킨 항생 펩타이드 및 이의 용도
KR101970876B1 (ko) * 2017-05-10 2019-04-19 건국대학교 산학협력단 D-라이신 치환을 통해 항균 효과를 증진시킨 항생 펩타이드 및 이의 용도
KR101970875B1 (ko) * 2017-05-10 2019-04-19 건국대학교 산학협력단 글루탐산 치환을 통해 항균 효과를 증진시킨 항생 펩타이드 및 이의 용도
CN106496307B (zh) * 2016-11-09 2019-11-01 湖南科技学院 一种新的抗菌肽及其用途
CN108503690B (zh) * 2017-02-28 2020-07-03 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
WO2018157773A1 (zh) 2017-02-28 2018-09-07 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
WO2020048996A1 (en) 2018-09-06 2020-03-12 ETH Zürich Self-assembling globular proteins and uses thereof
CN111388374B (zh) * 2020-04-11 2022-09-06 百草堂(湖北)制药有限公司 一种洗发露
EP4277917A4 (en) 2021-01-14 2024-06-19 Biocatalyst LLC Compositions and methods for peptide production
CN116874613B (zh) * 2023-09-06 2023-11-17 南京华盖制药有限公司 一种广谱高效的抗菌多肽aph143及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504761D0 (en) 1995-03-09 1995-04-26 Unilever Plc Amphiphilic peptide and analogs thereof
KR100263583B1 (ko) * 1997-05-28 2000-08-01 박종헌 항균 펩타이드의 대량 제조방법 및 그에 유용한 플라즈미드 벡타
WO2000031279A2 (en) * 1998-11-20 2000-06-02 Micrologix Biotech Inc. Producing antimicrobial cationic peptides as fusion proteins
US7288391B2 (en) * 2001-06-06 2007-10-30 University Of Wyoming Expression of spider silk proteins in higher plants
KR100438416B1 (ko) 2001-09-19 2004-07-02 학교법인조선대학교 Ｃａ－ｍａ 펩타이드의 아미노산 중 하나 또는 그 이상을치환하여 ＋ 전극과 소수성 영역이 증가된 신규한펩타이드 및 그를 포함하는 약학적 조성물
DE60215534T2 (de) 2001-11-20 2007-09-20 Novozymes A/S Antimikrobielle polypeptide aus pseudoplectania nigrella
US20030219854A1 (en) 2002-03-21 2003-11-27 Micrologix Biotech Inc. Methods for producing modified anti-infective peptides
JP4472998B2 (ja) 2002-04-22 2010-06-02 ダウ グローバル テクノロジーズ インコーポレイティド 低コストのペプチド製造
CA2519023C (en) 2003-03-17 2014-05-20 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
ES2525095T3 (es) * 2004-07-22 2014-12-17 Amsilk Gmbh Proteínas recombinantes de la seda de araña
RU2421463C2 (ru) * 2005-08-29 2011-06-20 АЭмЗильк ГмбХ Способ модификации белка шелка пауков, модифицированный белок шелка пауков, кодирующая его последовательность нуклеиновой кислоты, вектор и клетка-хозяин для его экспрессии
US7709227B2 (en) 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
CN101370556A (zh) 2006-01-20 2009-02-18 巴斯夫欧洲公司 蛋白质微粒在化妆品中的用途
CA2685308A1 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2008155304A1 (de) * 2007-06-20 2008-12-24 Basf Se Synthetische repetitive proteine, deren herstellung und verwendung
CA2708554C (en) * 2007-12-21 2014-04-22 Basf Se Anti-dandruff compositions containing peptides

Also Published As

Publication number Publication date
NZ596735A (en) 2013-10-25
RU2548815C2 (ru) 2015-04-20
JP5730293B2 (ja) 2015-06-10
EP2437769B1 (de) 2019-09-25
BRPI1011144A2 (pt) 2016-10-25
WO2010139736A2 (de) 2010-12-09
EP2437769A2 (de) 2012-04-11
KR101812842B1 (ko) 2017-12-27
AU2010255732B8 (en) 2014-03-13
TWI429750B (zh) 2014-03-11
CN102724992A (zh) 2012-10-10
ES2763168T3 (es) 2020-05-27
WO2010139736A3 (de) 2011-03-10
KR20120014940A (ko) 2012-02-20
TW201103981A (en) 2011-02-01
CN102724992B (zh) 2016-05-18
AU2010255732A8 (en) 2014-03-13
KR20140127344A (ko) 2014-11-03
AU2010255732B2 (en) 2013-09-12
AR076977A1 (es) 2011-07-20
KR101834018B1 (ko) 2018-03-05
CA2763626A1 (en) 2010-12-09
BRPI1011144B8 (pt) 2021-05-25
ECSP12011577A (es) 2012-02-29
PE20121033A1 (es) 2012-08-02
CR20110619A (es) 2012-02-09
US20120088268A1 (en) 2012-04-12
BRPI1011144B1 (pt) 2021-02-02
US9481719B2 (en) 2016-11-01
MX2011012906A (es) 2012-02-01
AU2010255732A1 (en) 2011-12-22
JP2012528579A (ja) 2012-11-15
IL216619A0 (en) 2012-02-29
NZ615847A (en) 2014-11-28
RU2011153757A (ru) 2013-07-20

Similar Documents

Publication Publication Date Title
CR20110619A (es) Produccion recombinante de peptidos
CY1125705T1 (el) Πρωτεϊνες προσδεσης καλλικρεϊνης πλασματος
MX390940B (es) Medio de cultivo celular complementado con taurina y metodos de uso.
CL2015000757A1 (es) Una proteina
MX2014005728A (es) Anticuerpos especificos para antigeno de la superficie celular de trofoblasto-2 y sus usos.
UA115120C2 (uk) Спосіб застосування химерного поліпептиду фактора ix
EA201690529A1 (ru) Способы модификации клетки-хозяина
CL2010001425A1 (es) Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina.
AU2012257942A8 (en) Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same
BR112012026379A2 (pt) métodos para gerar proteína endogenamente marcada
CL2011000672A1 (es) Anticuerpo que se une a il-17 humana; acido nucleico que lo codifica; vector de expresion; linea celular; metodo de produccion; composicion farmaceutica que lo comprende y su uso para tratar artritis reumatoidea entre otras enfermedades.
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
CL2009000210A1 (es) Acidos nucleicos que comprenden una secuencia que codifica un peptido de transito a plastidios de una glaucosafita enlazada a una segunda secuencia que codifica un peptido heterologo; metodo para la expresion estable de un polipeptido heterologo en una planta; polipeptido aislado codificado por el acido nucleico descrito anteriormente.
PE20151613A1 (es) Construcciones de anticuerpos para cdh19 y cd3
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
CL2012002700A1 (es) Anticuerpo humanizado capaz de logarse especificamente a receptores de quimioquina 4 (cxcr4); molecula de acido nucleico aislada que codifica dicho anticuerpo; vector y célula que comprenden dicho acido nucleico; composicion que comprende dicho anticuerpo; proceso de deteccion in vitro de la presencia y/o la ubicacion de un tumor que expresa cxcr4.
ECSP13012440A (es) Anticuerpos anti-fap y métodos de uso
CL2008002690A1 (es) Vector aislado que comprende un acido nucleico que codifica una enzima que produce un isoprenoide con dos fosfatos y un promotor que permite la expresion en un cloroplasto; celula huesped que lo contiene y metodo para producir un isoprenoide.
CL2012002125A1 (es) Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito.
AR075029A1 (es) Metodo para producir una proteina o un peptido fisiologicamente activo usando un fragmento de inmunoglobulina
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
EP2516624A4 (en) CELL LINE 3M
CL2008003660A1 (es) Metodo para obtener un peptido insulinotropico tipo glp-1 mediante la union de fragmentos del mismo ya sea en solucion o en fase solida; y peptidos intermediarios aqui empleados.
AR089830A1 (es) Acido nucleico, vector de expresion, celula bacteriana, celula de planta de citrus y metodo de expresion de un acido nucleico exogeno en la planta de citrus
WO2018148289A3 (en) Duplex adapters and duplex sequencing